
Suven Life Sciences to Present Alzheimer's Drug Data at CTAD Conference
Suven Life Sciences will present clinical progress on its investigational drug candidates, Masupirdine (SUVN-502) and Tenaclidine (SUVN-I6107), at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Conference in Boston, USA. The presentations will cover baseline demographic and clinical characteristics of the Phase-3 Masupirdine study for agitation in Alzheimer's patients, and the Phase-1 safety, tolerability, and pharmacokinetics of Tenaclidine in healthy subjects. The company anticipates topline results for the Masupirdine study in Q2-2027 and is encouraged by Tenaclidine's findings, planning to advance it to patient studies. This highlights Suven's commitment to developing innovative therapies for CNS disorders.
Key Highlights
- Suven to present Phase-3 Masupirdine and Phase-1 Tenaclidine data at CTAD.
- Masupirdine study for Alzheimer's agitation shows consistent baseline characteristics.
- Tenaclidine Phase-1 study shows positive safety and pharmacokinetic profile.
- Topline results for Masupirdine Phase-3 expected in Q2-2027.
- Company advancing innovative CNS disorder therapies.
Price Impact
More from SUVEN